SITC 2026: A Preview of Cancer Immunotherapy's Largest Annual Gathering

What This Article Covers

This November, the Society for Immunotherapy of Cancer (SITC) will hold its 41st Annual Meeting & Pre-Conference Programs in Phoenix, Arizona — one of the field's most closely watched gatherings for researchers, clinicians, and industry teams working on checkpoint inhibitors, cell-based therapies, and other immune-based approaches to cancer. This preview covers the confirmed dates and venue, what the meeting typically involves, who it is designed for, and how readers can follow or register for it.

What Is SITC, and Why This Meeting Matters

SITC is a nonprofit medical professional society focused on advancing the science and application of cancer immunotherapy. Its Annual Meeting has grown into one of the largest dedicated cancer immunotherapy conferences in the world, drawing basic scientists, translational researchers, oncologists, regulators, and biotech and pharma representatives to share late-breaking data, present abstracts, and network around a single organizing theme: harnessing the immune system against cancer. Because the meeting sits at the intersection of academic research and clinical/commercial development, it is frequently a venue where new trial data, biomarker findings, and emerging combination strategies are first discussed publicly.

Confirmed Dates and Location

According to SITC's own event site, the 2026 Annual Meeting runs Wednesday, November 4 through Sunday, November 8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. The program is structured with pre-conference sessions ahead of the main meeting days, a format SITC has used in recent years to accommodate specialized workshops and early-career programming before the general scientific sessions begin.

What to Expect on the Agenda

As of this writing, SITC notes that its detailed session schedule is still being finalized and is subject to change, so specific talk titles and speaker lineups aren't yet locked in. That said, based on the society's stated mission and the structure of recent annual meetings, attendees can generally expect programming spanning immune checkpoint blockade, adoptive and engineered cell therapies, tumor microenvironment and biomarker research, and combination-therapy strategies — alongside abstract-driven poster and oral presentation sessions. Readers who want the most current agenda should check SITC's official schedule page directly as it fills in over the coming weeks.

Who It's For — and How to Get Involved

The meeting is aimed primarily at working scientists and clinicians in immuno-oncology, but SITC has built out participation pathways for a broader audience:

• Abstract submissions (including a dedicated Early Career Investigator Award track) are open through SITC's official submission portal.
• An Early Career Scientist Activities track and an Undergraduates in STEM Program offer entry points for trainees and students.
• Career Connections networking sessions and social events, including the meeting's "CheckPoints Party," are built into the schedule for informal networking.
• Registration rates and tiers are published on SITC's registration page, with different pricing for members, non-members, and trainees.

For our readers who work in or study regenerative and immune-based cancer therapies, a meeting like this is a useful marker of where the field's mainstream research consensus is heading — distinct from claims made by individual clinics or unproven treatment providers, which this publication does not endorse or evaluate.

Bottom Line

SITC 2026 is a real, confirmed event — the 41st Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer, running November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. Full session details are still being finalized, so readers planning to attend or follow the meeting should monitor SITC's official site for updates rather than relying on secondary previews, including this one, for granular program specifics.